Kanzhun (NASDAQ:BZ) Earns Buy Rating from Analysts at HSBC

HSBC initiated coverage on shares of Kanzhun (NASDAQ:BZ – Free Report) in a research report sent to investors on Friday, MarketBeat reports. The brokerage issued a buy rating and a $30.00 price objective on the stock. Other analysts have also issued research reports about the stock. New Street Research raised shares of Kanzhun from a […]

Leave a Reply

Your email address will not be published.

Previous post Coherus BioSciences (NASDAQ:CHRS) Rating Reiterated by HC Wainwright
Next post Raymond James Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $70.00